Prospective, Double-Blind, Randomized, Placebo-Controlled Comparison of Acetazolamide Versus Ibuprofen for Prophylaxis Against High Altitude Headache: The Headache Evaluation at Altitude Trial (HEAT)
- 30 September 2010
- journal article
- research article
- Published by SAGE Publications in Wilderness & Environmental Medicine
- Vol. 21 (3), 236-243
- https://doi.org/10.1016/j.wem.2010.06.009
Abstract
High altitude headache (HAH) is the most common neurological complaint at altitude and the defining component of acute mountain sickness (AMS). However, there is a paucity of literature concerning its prevention. Toward this end, we initiated a prospective, double-blind, randomized, placebo-controlled trial in the Nepal Himalaya designed to compare the effectiveness of ibuprofen and acetazolamide for the prevention of HAH. Three hundred forty-three healthy western trekkers were recruited at altitudes of 4280 m and 4358 m and assigned to receive ibuprofen 600 mg, acetazolamide 85 mg, or placebo 3 times daily before continued ascent to 4928 m. Outcome measures included headache incidence and severity, AMS incidence and severity on the Lake Louise AMS Questionnaire (LLQ), and visual analog scale (VAS). Two hundred sixty-five of 343 subjects completed the trial. HAH incidence was similar when treated with acetazolamide (27.1%) or ibuprofen (27.5%; P = .95), and both agents were significantly more effective than placebo (45.3%; P = .01). AMS incidence was similar when treated with acetazolamide (18.8%) or ibuprofen (13.7%; P = .34), and both agents were significantly more effective than placebo (28.6%; P = .03). In fully compliant participants, moderate or severe headache incidence was similar when treated with acetazolamide (3.8%) or ibuprofen (4.7%; P = .79), and both agents were significantly more effective than placebo (13.5%; P = .03). Ibuprofen and acetazolamide were similarly effective in preventing HAH. Ibuprofen was similar to acetazolamide in preventing symptoms of AMS, an interesting finding that implies a potentially new approach to prevention of cerebral forms of acute altitude illness.Keywords
This publication has 29 references indexed in Scilit:
- Sensitization of meningeal nociceptors: inhibition by naproxenEuropean Journal of Neuroscience, 2008
- Mechanisms of action of acetazolamide in the prophylaxis and treatment of acute mountain sicknessJournal of Applied Physiology, 2007
- Response Properties of Dural Nociceptors in Relation to HeadacheJournal of Neurophysiology, 2006
- High Altitude Headache. A Prospective Study of its Clinical CharacteristicsCephalalgia, 2005
- Prospective validation of clinically important changes in pain severity measured on a visual analog scaleAnnals of Emergency Medicine, 2001
- Over-the-counter analgesics and antipyretics: A critical assessmentClinical Therapeutics, 2000
- HIGH ALTITUDE INCREASES CIRCULATING INTERLEUKIN-6, INTERLEUKIN-1 RECEPTOR ANTAGONIST AND C-REACTIVE PROTEINCytokine, 2000
- The Minimum Clinically Important Difference in Physician–assigned Visual Analog Pain ScoresAcademic Emergency Medicine, 1996
- Plasma prostaglandins, leukotrienes and thromboxane in acute high altitude hypoxiaRespiration Physiology, 1991
- The Effect of Naproxen on Acute Mountain Sickness and Vascular Responses to HypoxiaThe American Journal of the Medical Sciences, 1986